NCT05638802 - A Study of DS-7011a in Patients With Systemic Lupus Erythematosus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

DS-7011a

20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57

DRUG

Placebo

Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57

Trial Locations (12)

Joint & Muscle Research Institute, Charlotte

Office of Tory P. Sullivan, M.D. - North Miami Beach, North Miami Beach

West Broward Rheumatology Associates, Tamarac

Pinnacle Research Group LLC, Anniston

Revival Research Institute, LLC, Troy

Oakland Hills Dermatology, Auburn Hills

Trinity Health Center Medical Arts, Minot

MediSearch Clinical Trials, Saint Joseph

The University of Kansas Medical Center, Kansas City

Arkansas Research Trials, North Little Rock

Metroplex Clinical Research Center, LLC, Dallas

Precision Comprehensive Clinical Research Solutions, Colleyville